Association of clinical and demographic factors in invasive candidiasis caused by fluconazole-resistant Candida species: A study in 15 hospitals, Medellín, Colombia 2010-2011

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 2, 2014, Pages 280-286

  Maldonado, Natalia Andrea ^a,b   Cano, Luz Elena ^c,d   De Bedout, Catalina ^c   Arbeláez, Carlos Alberto ^e   Roncancio, Gustavo ^f,g   Tabares, Ángela María ^c   Robledo, Carlos Gonzalo ^a,b   Robledo, Jaime ^a,b,c,g  

^a Clinic el Rosario   (Colombia)

^b Grupo GERMEN   (Colombia)

^c Unidad de Biología Celular y Molecular   (Colombia)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^e Clinica Universitaria Bolivariana   (Colombia)

^f CardioVID Clinic   (Colombia)

^g UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

Author keywords

Antifungal susceptibility; Candidiasis; Fluconazole resistance; Risk factors

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; STEROID; TUBERCULOSTATIC AGENT; VORICONAZOLE;

ABDOMINAL FLUID; ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BILE FLUID; BLOOD; BODY FLUID; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CASE CONTROL STUDY; CHILD; CLINICAL STUDY; COLOMBIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FLUCONAZOLE RESISTANT CANDIDA; FLUCONAZOLE SUSCEPTIBLE CANDIDA; FUNGUS ISOLATION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PATHOGENESIS; PICHIA GUILLIERMONDII; PLEURA FLUID; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERY ELDERLY; CANDIDIASIS, INVASIVE; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLOMBIA; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84900496524     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.02.003     Document Type: Article

References (38)

1. Arendrup M.C., Bruun B., Christensen J.J., Fuursted K., Johansen H.K., Kjaeldgaard P., et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011, 49(1):325-334.
2. Bassetti M., Righi E., Costa A., Fasce R., Molinari M.P., Rosso R., et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 6:21.
3. Bates D.W., Yung D.T. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today 2003, 39:801-813.
4. Ben-Ami R., Olshtain-Pops K., Krieger M., Oren I., Bishara J., Dan M., et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012, 56(5):2518-2523.
5. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. Third Informational Supplement. CLSI Document M27-S 2008, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA.
6. Eggimann P., Bille J., Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011, 1:37.
7. Falagas M.E., Roussos N., Vardakas K.Z. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010, 14(11):954-966.
8. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43(1):25-31.
9. Garnacho-Montero J., Díaz-Martín A., García-Cabrera E., Ruiz Pérez de Pipaón M., Hernández-Caballero C., Aznar-Martín J., et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010, 54(8):3149-3154.
10. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37(9):1172-1177.
11. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29(11):996-1011.
12. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48(12):1695-1703.
13. Lee I., Fishman N.O., Zaoutis T.E., Morales K.H., Weiner M.G., Synnestvedt M., et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009, 169(4):379-383.
14. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005, 49(11):4555-4560.
15. Lortholary O., Desnos-Ollivier M., Sitbon K., Fontanet A., Bretagne S., Dromer F., et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011, 55(2):532-538.
16. Masiá Canuto M., Gutiérrez Rodero F., Ortiz de la Tabla Ducasse V., Hernández Aguado I., Martín González C., Sánchez Sevillano A., et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2000, 19(8):593-601.
17. Mikulska M., Bassetti M., Ratto S., Viscoli C. Invasive candidiasis in non-hematological patients. Mediterr J Hematol Infect Dis 2011, 3(1):e2011007.
18. Nucci M., Queiroz-Telles F., Tobón A.M., Restrepo A., Colombo A.L. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010, 51(5):561-570.
19. Del Palacio A., Alhambra A., Cuétara M.S. Factores de riesgo de la candidiasis invasora: estratificación. Rev Iberoam Micol 2006, 23(1):29-31.
20. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37(5):634-643.
21. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20(1):133-163.
22. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46(1):150-156.
23. Pfaller M.A., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Kroeger J., et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009, 47(10):3185-3190.
24. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for Fluconazol and Candida time for harmonization of CLSI and EUCAST broth microdilution. Drug Resist Updat 2010, 13(6):180-195.
25. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48(4):1366-1377.
26. Pfaller M.A., Andes D., Arendrup M.C., Diekema D.J., Espinel-Ingroff A., Alexander B.D., et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011, 70(3):330-343.
27. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14(3):164-176.
28. Pfaller M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011, 49(1):396-399.
29. Playford E.G., Marriott D., Nguyen Q., Chen S., Ellis D., Slavin M., et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008, 36(7):2034-2039.
30. Sims C.R., Paetznick V.L., Rodriguez J.R., Chen E., Ostrosky-Zeichner L. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol 2006, 44(6):2105-2108.
31. Torres N.A., Alvarez C.A., Rondón M.A. Evaluación mediante tres técnicas de susceptibilidad a fluconazol en especies de Candida aisladas en pacientes con infecciones invasoras. Bogotá - Colombia. Rev Chil Infect 2009, 26(2):135-143.
32. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23(4):317-322.
33. Tumbarello M., Sanguinetti M., Trecarichi E.M., La Sorda M., Rossi M., de Carolis E., et al. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. J Antimicrob Chemother 2008, 62(6):1379-1385.
34. Villar L.A., Quijano F.A., Cespedes J.I., Torres A., De Bedout C. Prevalencia de patrones de sensibilidad al fluconazol de las especies de Candida aisladas de pacientes de unidades de cuidados intensivos de Bucaramanga-Colombia. Infectio 2004, 8(3):185-193.
35. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302(21):2323-2329.
36. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Hospital acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148(12):2642-2645.
37. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008, 29(10):978-980.
38. Zuluaga A., De Bedout C., Agudelo C.A., Hurtado H., Arango M., Restrepo A., et al. Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001-2007). Rev Iberoam Micol 2010, 27(3):125-129.